117 related articles for article (PubMed ID: 20706793)
1. Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma.
Weng CJ; Tsai CM; Chen YC; Hsieh YH; Lin CW; Liu YF; Su SC; Chen MK; Yang SF
Ann Surg Oncol; 2010 Dec; 17(12):3394-401. PubMed ID: 20706793
[TBL] [Abstract][Full Text] [Related]
2. Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.
Weng CJ; Lin CW; Chung TT; Tsai CM; Chen MK; Yang SF
Ann Surg Oncol; 2011 Mar; 18(3):805-12. PubMed ID: 21125336
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
4. Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma.
Chen TY; Li YC; Liu YF; Tsai CM; Hsieh YH; Lin CW; Yang SF; Weng CJ
Ann Surg Oncol; 2011 Aug; 18(8):2348-56. PubMed ID: 21298348
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
[TBL] [Abstract][Full Text] [Related]
6. Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Shih CM; Kuo WH; Lin CW; Chen W; Cheng WE; Chen SC; Lee YL
Clin Chim Acta; 2011 Jan; 412(1-2):194-8. PubMed ID: 20937265
[TBL] [Abstract][Full Text] [Related]
7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Tee YT; Wang PH; Tsai HT; Lin LY; Lin HT; Yang SF; Hsieh YH; Ying TH
J Surg Oncol; 2012 Aug; 106(2):204-8. PubMed ID: 22354580
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
11. A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
Przybylowska K; Smolarczyk K; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B
J Exp Clin Cancer Res; 2001 Dec; 20(4):569-72. PubMed ID: 11876553
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma].
Zheng Q; Tang Z; Wu Z; Shi D; Song H
Zhonghua Wai Ke Za Zhi; 1998 Aug; 36(8):474-6. PubMed ID: 11825444
[TBL] [Abstract][Full Text] [Related]
13. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma.
Chien MH; Yeh KT; Li YC; Hsieh YH; Lin CH; Weng MS; Kuo WH; Yang SF
J Surg Oncol; 2011 Sep; 104(3):299-304. PubMed ID: 21462191
[TBL] [Abstract][Full Text] [Related]
14. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
15. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
16. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
17. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
19. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
20. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma.
Weng CJ; Hsieh YH; Tsai CM; Chu YH; Ueng KC; Liu YF; Yeh YH; Su SC; Chen YC; Chen MK; Yang SF
Ann Surg Oncol; 2010 Jul; 17(7):1808-15. PubMed ID: 20119675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
